The eye maintains comfort and clarity through a coordinated biological system. One useful way to understand this system is the lacrimal functional unit. The lacrimal functional unit includes the lacrimal glands, ocular surface, eyelids, meibomian glands, conjunctival goblet cells, sensory nerves, and neural reflex pathways that help regulate tearing and blinking. These structures work together […]
Ocular GVHD (oGVHD) begins with transplant immunology, but its effects can become intensely local. After allogeneic hematopoietic stem cell transplantation, the donor immune system may recognize recipient tissues as foreign. In chronic graft-versus-host disease, immune-mediated inflammation and fibrosis can affect multiple organs, including the skin, mouth, gastrointestinal tract, liver, lungs, fascia, genital tract, and eyes. […]
Ocular graft-versus-host disease, often abbreviated as oGVHD, is sometimes described as a severe form of dry eye. That shorthand is understandable, but it is incomplete. Dry eye is one of the most visible ways oGVHD is experienced by patients. Burning, grittiness, dryness, light sensitivity, foreign body sensation, tearing, and fluctuating vision are common complaints. But […]
Most people think of tears as something that appears when we cry. In ocular health, tears are much more than water. They are a living, protective system that supports comfort, vision, and the health of the ocular surface. The tear film coats the front of the eye every time we blink. It helps keep the […]
Signal12 is a Phase 3-ready ophthalmic drug company. Our proprietary topical drug, Pro-ocular™, has proven safe and effective in Phase 2 clinical studies, demonstrating significant reductions in the signs and symptoms of ocular Graft-versus-Host Disease (oGvHD)—a chronic, debilitating condition following an allogeneic stem cell transplant. Pro-ocular™ is the only effective treatment for oGvHD, employing transappendageal delivery to precisely target the ophthalmic branch of the trigeminal nerve
Signal12 is actively raising capital to complete its Phase 3 clinical trials and bring Pro-ocular™ to market. For information on investment opportunities, please email Neil Edwards at nedwards@signal12inc.com. The company has offices in Greenwich, CT and Boston, MA.
© 2026 Signal 12 Inc. | Email: info@signal12inc.com